HRTS
Tema Obesity & Cardiometabolic ETF · NAS
- Category Equity
- Expense Ratio 0.75%
- Listing Date Nov 21, 2023
- Volume 8,621.0
- Market Cap (AUM) $62.4M
Performance
+0.25%
1W
+3.88%
1M
-0.73%
3M
+22.7%
6M
+6.73%
YTD
+22.7%
1Y
Top Holdings
-
Name
Symbol%Assets
- Vertex Pharmaceuticals IncorporatedVRTX5.69%
- Amgen Inc.AMGN5.62%
- Eli Lilly and CompanyLLY4.97%
- Novo Nordisk A/S Class BNOVO.B4.89%
- DexCom, Inc.DXCM4.20%
- Crinetics Pharmaceuticals IncCRNX3.11%
- Insulet CorporationPODD2.98%
- Edwards Lifesciences CorporationEW2.92%
- Medtronic PlcMDT2.90%
- BridgeBio Pharma, Inc.BBIO2.87%
Technical Analysis of HRTS 2024-05-10
Overview:
In analyzing the technical indicators for HRTS over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive assessment of the stock's potential price movement. By examining these key factors, we aim to offer valuable insights and predictions for the next few days.
Trend Indi...
Recent News & Updates
- 2024-04-21 23:10
10 Best Performing Biotech ETFs in 2024(Insidermonkey)
- 2024-03-13 12:40
'Continued innovation' is key when investing in weight loss trend(Yahoo Finance Video)
Page 1 of 1
previousnext